Michael Lau is a Respiratory physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
39 Brentwood Rd Ste 102
Bay Shore, NY 117068031
Telephone
631-666-5864Provider last certified this registry record 23 Jun 2020.
Clinical trials
- Directed Ablation of Uterine Fibroids Using a Noninvasive Approach
Sponsor: Mirabilis Medica, Inc.
- Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids
Sponsor: Mirabilis Medica, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
83.5%Corticosteroid45.9%Trelegy Ellipta60%Breo Ellipta11%Symbicort9%Budesonide-Formoterol Fumarate7%Fluticasone Propionate6%Breztri Aerosphere4%Breyna3%Part D<11 patientsbeta2-Adrenergic Agonist29.9%Albuterol Sulfate Hfa95%Ventolin Hfa5%Part D≥209 patients+ 3 more classes in this area
Metabolism & gastrointestinal
9.9%Corticosteroid9.3%Prednisone100%Part D≥57 patientsH2 blocker0.6%Famotidine100%Part D<11 patientsAnti-infectives
6.5%Macrolide Antimicrobial3.4%Azithromycin100%Part D≥23 patientsTetracycline-class Drug1.7%Doxycycline Hyclate100%Part D≥28 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”